CT scan vs. needle biopsy: which is better for spotting pancreatic cancer?
NCT ID NCT07424456
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will compare two methods—triphasic CT scans and endoscopic ultrasound-guided biopsies—to see which one more accurately tells benign from malignant pancreatic lesions. Researchers will enroll 50 adults with pancreatic lesions found on initial imaging. The goal is to determine if the less invasive CT scan can match the accuracy of a biopsy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could show that a CT scan is as accurate as a biopsy for diagnosing pancreatic lesions, potentially reducing the need for invasive procedures.
- What could go wrong
- This is a small, early study with only 50 participants, so results may not apply to everyone. The CT scan might still miss some cancers that a biopsy would catch.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients (age\>18 years) presenting with focal pancreatic lesions detected on initial imaging.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * \*Adult patients (age\>18 years) presenting with focal pancreatic lesions detected on initial imaging. * Patients referred for further evaluation by triphasic CT and/or EUS-guided biopsy. * Patients able to provide informed consent Exclusion Criteria: * Previous pancreatic surgery. * Known metastatic disease at presentation. * Contraindications to contrast-enhanced CT (e.g. severe renal impairment, contrast allergy) * Contraindications to EUS or biopsy (e.g., coagulopathy uncorrected, severe cardiopulmonary instability). * Pregnancy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CT scan are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sharper CT scans may solve a lung disease diagnostic puzzle
- New heat therapy for pancreatic lesions tested in 100-Patient registry
- Nanomechanical biopsy could revolutionize pancreatic cancer care
- Can brain wave patterns predict epilepsy after a stroke?
- New biopsy device may improve pancreatic cancer diagnosis
- Are ER CT scans overused? new study investigates